Development and characterization of dendritic cell internalization and activation assays contributing to the immunogenicity risk evaluation of biotherapeutics.

Fiche publication

Date publication

août 2024

Journal

Frontiers in immunology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROHR Olivier

Tous les auteurs :
Siegel M, Padamsey A, Bolender AL, Hargreaves P, Fraidling J, Ducret A, Hartman K, Looney CM, Bertinetti-Lapatki C, Rohr O, Hickling TP, Kraft TE, Marban-Doran C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39229274

Résumé

Immunogenicity refers to the ability of a substance, such as a therapeutic drug, to elicit an immune response. While beneficial in vaccine development, undesirable immunogenicity can compromise the safety and efficacy of therapeutic proteins by inducing anti-drug antibodies (ADAs). These ADAs can reduce drug bioavailability and alter pharmacokinetics, necessitating comprehensive immunogenicity risk assessments starting at early stages of drug development. Given the complexity of immunogenicity, an integrated approach is essential, as no single assay can universally recapitulate the immune response leading to the formation of anti-drug antibodies.